Poster – Development of a new liver-on-chip including BIOMIMESYS® technology for mimicking the liver extracellular matrix: first results and perspectives

Published by Grégory MAUBON on

Objective: to develop a new liver-on-chip model that includes a relevant 3D matrix for hepatic cell growth and function with the use of of BIOMIMESYS® Liver hydroscaffold for a physiological 3D hepatocyte culture.

Ask for high quality link by putting your email below

Please, double check your email!

View and download on Slideshare (low quality) https://www.slideshare.net/hcspharma/development-of-a-new-liveronchip-including-biomimesys-technology-for-mimicking-the-liver-extracellular-matrix-first-results-and-perspectives-165363388

Categories: Biomimesysbiomimesys_liverPostersResources
Tags:

Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

3 Comments

Artifical Intelligence and HCS in 3D cell culture: the perfect team to revolutionize drug discovery! | HCS Pharma · September 10, 2019 at 2:05 pm

[…] Organ-on-a-chip technology using BIOMIMESYS® […]

Reply

Kick-off meeting of ANR-funded project MIMLIVEROnChip | HCS Pharma · October 8, 2019 at 2:02 pm

[…] Don’t forget to take a look at our poster : “Development of a new liver-on-chip including BIOMIMESYS® technology for mimicking the liver extrace…“ […]

Reply

Feedback from Molecular Devices' User Meeting in Leiden | HCS Pharma · March 24, 2020 at 2:01 pm

[…] NO, BIOMIMESYS is not a hydrogel and YES, it can be cast in biochips! […]

Reply

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Related Posts

AI4HCS

Artificial intelligence to improve 3D cell culture : a milestone for HCS pharma

As you may now, in HCS Pharma we strongly believe that the critical point of the human health evolution in next years is the in vitro 3D cell culture, especially for complex diseases like cancer [1]. It’s why we work hard on our exclusive BIOMIMESYS® technology. As experts in HCS and cell imaging, we must master all the process : 3D biological models, 3D cell culture, volumetric pictures acquisition, 3D reconstruction and segmentation of cells and ECM compounds, 3D parameters extraction and, of course, biological interpretations. As explained in our VisuAI R&D project, the 3D reconstruction and segmentation step is not simple.

Biomimesys

Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping

A publication from R. Lane et al, described the use of Small extracellular vesicles (sEVs) reservoir as a biomarker for Glioblastoma tumor subtyping. In this publication Astrocytes, Glioblastoma cell lines, and Glioblastoma patient-derived stem cells were grown in BIOMIMESYS® hydroscaffold. Read more…

Biomimesys

BIOMIMESYS hydroscaffold for your coronavirus-related research in 3D

Clinicians and researchers worldwide are actively studying the mechanisms governing the infection of humans by SARS-CoV-2 and its consequences on their health, with the objective is to find effective therapies. We all aknowledge their important Read more…